Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tegafur-uracil + leucovorin + oxaliplatin + S-1
- Development stage
- Unknown
- Lead developer
- Lanzhou University
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
TEGAFOX + S-1 is an investigational sequential adjuvant chemotherapy regimen primarily studied for the treatment of stage II-III gastric cancer following radical resection. The regimen consists of two phases: TEGAFOX, which is a combination of tegafur-uracil (UFT), leucovorin, and oxaliplatin, followed sequentially by S-1 (a combination of tegafur, gimeracil, and oteracil potassium). This approach utilizes multiple fluoropyrimidine-based agents and a platinum-based agent to inhibit DNA synthesis and induce DNA damage. Specifically, tegafur is a prodrug of 5-fluorouracil (5-FU), which inhibits thymidylate synthase, while oxaliplatin forms DNA cross-links. Gimeracil and oteracil in the S-1 component serve to enhance 5-FU levels and reduce gastrointestinal toxicity, respectively. The regimen is being evaluated by Lanzhou University in Phase 2/3 clinical trials.
- Brand names
- TS-1TS1TS 1UFT
- Other names
- TEGAFOX sequential S-1TEGAFOX + S-1
02
Targets
TS (Thymidylate synthase)DNADPYD (Dihydropyrimidine dehydrogenase)
Beyond the preview
Go deeper on tegafur-uracil + leucovorin + oxaliplatin + S-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tegafur-uracil + leucovorin + oxaliplatin + S-1.